Zoledronic acid fails to match early promise for knee osteoarthritis

Promising initial results for the bisphosphonate zoledronic acid in knee osteoarthritis have not been replicated when tested in a randomised controlled trial, according to Australian results presented at the European League Against Rheumatism (EULAR) Congress in Amsterdam. Zoledronic acid did not alleviate knee OA-related pain or reduce the size of associated bone marrow lesions (BML) ...

Already a member?

Login to keep reading.

© 2021 the limbic